Cost-effectiveness of Bariatric Surgery for People with Morbid Obesity in South Korea

An, Sena; Park, Hae Young; Oh, Sung-Hee; Heo, Yoonseok; Park, Susan; Jeon, Soo Min

doi:10.1007/s11695-019-04122-w

Cited by 7 publications

(8 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A prospective multicenter clinical trial was conducted among 13 Korean university hospitals in conjunction with the Korean Society for Metabolic and Bariatric Surgery. It showed that bariatric surgery in patients with BMI ≥ 30 kg/m 2 was cost-effective and more effective than non-surgical treatment for the reduction of BMI and remission of obesity-related comorbidities [27,28]. Based on the results, public health care insurance covered bariatric/metabolic surgery for patients with BMI ≥ 30 kg/m 2 in January 2019.…”

Section: Discussionmentioning

confidence: 99%

Ten Years of Change in Bariatric/Metabolic Surgery in the Asia–Pacific Region with COVID-19 Pandemic: IFSO-APC National Reports 2021

et al. 2022

View full text Add to dashboard Cite

Background On November 25, 2021, the IFSO-Asia–Pacific Chapter (IFSO-APC) Virtual Meeting 2021 was held online, and the representatives from the Asia–Pacific region presented 10 years of change in bariatric/metabolic surgery and the influence of COVID-19 in the special session of “IFSO-APC National Reports 2010–2020”. We herein report the summarized data. Methods National bariatric/metabolic surgery data, which included the data of 2010 and 2020, were collected from the representatives using a questionnaire that consisted of 10 general questions. At the congress, the data were calculated and summarized. Results Thirteen of the 14 national societies responded to the survey. From 2010 to recent years, the populations of individuals with obesity (BMI ≥ 30 kg/m2) and individuals with diabetes both significantly increased. Eight countries and regions expanded the lower limit of criteria for bariatric surgery by 2–5 kg/m2 (BMI), and 5 countries newly established criteria for metabolic surgery in the last ten years. Sixty-nine percent of the countries currently run public health insurance systems, which doubled from 2010. The number of bariatric surgeons and institutions increased more than threefold from 2010. In 2010, 2019, and 2020, surgeons in IFSO-APC societies performed 18,280, 66,010, and 49,553 bariatric/metabolic surgeries, respectively. Due to the COVID pandemic, restriction policies significantly reduced access to surgery in South and Southeast Asian countries. The biggest changes included increased numbers of bariatric surgeons and institutions, operation numbers, public insurance coverage, raising awareness, and national registry systems. Conclusion For the last 10 years, bariatric/metabolic surgery has rapidly grown in the Asia–Pacific region.

show abstract

Section: Discussionmentioning

confidence: 99%

Ten Years of Change in Bariatric/Metabolic Surgery in the Asia–Pacific Region with COVID-19 Pandemic: IFSO-APC National Reports 2021

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Therefore, it becomes critical to identify, examine, and provide cost‐effective treatments for individuals with severe obesity. Bariatric surgery is an established treatment for severe obesity, shown to be cost‐effective in the US (8), Europe (9), Asia (10), South America (11), and Australia (12). However, in patients with severe obesity who have binge eating disorder or loss‐of‐control eating, which is common to all binges, bariatric surgery may have a significantly smaller impact on long‐term weight loss (13).…”

Section: Introductionmentioning

confidence: 99%

Can responsive deep brain stimulation be a cost‐effective treatment for severe obesity?

Mahajan

Ojukwu

Azagury

et al. 2022

Obesity

View full text Add to dashboard Cite

The global obesity epidemic has an undeniably high economic burden, with its associated annual medical spending in the US alone totaling $150 billion in 2010 (1). The financial cost per patient with obesity is similarly high in other nations, including in low-and middle-income countries (2). At the turn of the 21st century, obesity accounted for up to 3% of a country's total health expenditures (3). In the years following, both the global prevalence of obesity and disease burden related to high BMI have steadily increased within every sociodemographic quintile (4). Most recently, the societal safety measures imposed during the COVID-19 pandemic will likely have long-term negative effects on the obesity epidemic (5).Notably, the relationship between BMI and health care costs is nonlinear, i.e., health care costs rise exponentially for the few individuals with the most severe obesity (6). Indeed, the 10% of the population of individuals with overweight/obesity with the highest BMI account for more than 60% of the global disease burden related to obesity (7). Therefore, it becomes critical to identify, examine, and provide cost-effective treatments for individuals with severe obesity. Bariatric surgery is an established treatment for severe obesity, shown to be cost-effective in the US (8), Europe (9), Asia (10), South America (11), and Australia (12). However, in patients with severe

show abstract

“…According to previous studies that focused on Koreans, bariatric surgery was found to be superior to conventional treatment in terms of weight reduction and maintenance in both short-term and long-term follow-up [ 30 ]. In addition, bariatric surgery in patients with a BMI of >30 kg/m 2 was more cost-effective than nonsurgical treatment in Koreans as well as Westerners [ 31 ]. Effects on comorbidities should also be highlighted; the type 2 DM remission effect was noted to be better in Asians than in non-Asian populations [ 32 ].…”

Section: Bariatric/metabolic Surgerymentioning

confidence: 99%

Restoration for the foregut surgery: bridging gaps between foregut surgery practice and academia

Shin

Park

Kwon

et al. 2021

J Minim Invasive Surg

View full text Add to dashboard Cite

Foregut surgery largely involves benign diseases, and not only malignant diseases. However, for foregut surgeons in Asia, this fact has not been extensively utilized in their clinical practice due to the high burden of gastric cancer surgery. Although the prevalence of gastroesophageal reflux disease (GERD) in Eastern Asia, including Korea, is increasing, antireflux surgery (ARS) is still a fairly rare procedure in Korea. ARS is effective as proton pump inhibitors and is cost-effective compared to continuous double-dose proton pump inhibitors in patients with severe GERD. Therefore, we should focus on ARS as a treatment option for GERD also in Asian population. Similarly, although bariatric/metabolic surgery is effective in weight reduction and diabetes mellitus (DM) remission in patients with morbid obesity or DM, bariatric/metabolic surgery is only performed in a limited number of patients. Given that the prevalence of obesity and DM is continuously increasing in Korea, bariatric/metabolic surgery should become an interest among Korean foregut surgeons and should be considered a treatment for obesity and DM. Furthermore, there are new surgical fields that can control both benign and malignant diseases. Oncometabolic surgery is a field under foregut surgery that treats both malignant and benign components of a condition, an example being the control of metabolic syndrome while performing gastric cancer surgery. Therefore, in future gastric cancer treatment, oncometabolic surgery can be applied to patients with gastric cancer accompanied by obesity or metabolic syndrome.

show abstract

Cost-effectiveness of Bariatric Surgery for People with Morbid Obesity in South Korea

Cited by 7 publications

References 36 publications

Ten Years of Change in Bariatric/Metabolic Surgery in the Asia–Pacific Region with COVID-19 Pandemic: IFSO-APC National Reports 2021

Ten Years of Change in Bariatric/Metabolic Surgery in the Asia–Pacific Region with COVID-19 Pandemic: IFSO-APC National Reports 2021

Can responsive deep brain stimulation be a cost‐effective treatment for severe obesity?

Restoration for the foregut surgery: bridging gaps between foregut surgery practice and academia

Contact Info

Product

Resources

About